ARQT

ARCUTIS BIOTHERAPEUTICS INC

ARQT·03969K108·US·Common Stock·Healthcare - Biotechnology-Activist

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is held by 151 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($276.5M), Polar Capital Holdings Plc ($173.2M), STATE STREET CORP ($152.7M). Net institutional sentiment: Mixed. In Q2 2026, 1 member of Congress and 83 funds bought ARQT.

151
Holders
(10 Elite)
$2.2B
Total Value
54% (154)
Consensus
83 buying - 71 selling
13F: Insider & Congress: Updated regularly
ARQT

Smart Money Verdict

View all
Loading verdict
Held by 151 funds
10 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Aug 28, 2026 · Activists Aug 14, 2026 · Congress Jun 8, 2026

InsiderCTCurran TerrieExercise 11K shAug 27, 2026
InsiderCTCurran TerrieExercise 27K shAug 27, 2026
InsiderCTCurran TerrieSell $279KAug 27, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
10.5M(+14.6%)$276.5M0.0%+53.65%
35
Increased
6.6M(+16.6%)$173.2M0.4%+74.14%
42
Decreased
5.8M(-7.5%)$152.7M0.0%+84.27%
0
Increased
5M(+2.4%)$130.8M0.0%+6.42%
31
Increased
4.5M(+5.5%)$116.7M0.0%+121.24%
32
Decreased
4.2M(-15.3%)$110.6M0.1%+159.06%
0
Increased
3.9M(+58.2%)$103.6M0.0%+32.22%
43
Increased
3.3M(+0.1%)$87.4M0.0%+63.81%
30
Increased
3M(+34.5%)$78.3M0.0%+10.12%
38
Decreased
3M(-2.1%)$78.2M0.0%+73.30%
0
Increased
2.4M(+24.3%)$63.7M0.0%+4.40%
36
Decreased
1.9M(-16.0%)$50.6M0.0%+145.17%
0
Increased
1.9M(+31.6%)$50.5M0.0%+52.36%
37
Increased
1.7M(+4.1%)$43.7M0.0%+72.19%
30
Decreased
1.3M(-69.5%)$34.4M0.4%+124.79%
0
Increased
1.3M(+16.9%)$32.9M0.0%-3.87%
34
Increased
1.2M(+7333.1%)$30.4M0.0%-3.55%
46
Increased
1.1M(+4.4%)$29.5M0.0%+71.63%
30
Increased
1.1M(+70.3%)$28.8M0.0%+46.28%
43
Increased
1.1M(+8.4%)$27.8M0.0%+58.38%
31

Showing 1-20 of 161

1 / 9
ARQTARQTARCUTIS BIOTHERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used